There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well as my own personal experience, I must fall in line and agree with an online published study that shows that men on ADT are likely to experience cognitive impairment of some type. The study was small, as all of the other studies have been, followed [...]
There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to suppress testosterone. What makes this class of drugs different is that it also avoids the flare phenomenon that is observed with the GnRH agonists like Lupron. The flare phenomenon, where the body initially pumps out additional levels of testosterone in response to the GnRH agonist [...]
Hormone Therapy (ADT) for Prostate Cancer Patients Might Provide Us Another Long Term Gift – Alzheimer’s Disease
Hormone therapy (ADT) is notorious for providing us with side effects. Some of these side effects are best described as ones that deteriorate our general quality of life. For example the most common one we all are familiar with is, of course, hot flashes. You could also add erectile dysfunction as well as loss of sexual desire to these common side effects. In most cases, if you are on intermittent therapy, when you move into an off period you will experience a period of side effect abetment, at least until you go back onto therapy. We also know that ADT [...]
Pamorelin (Trelstar® )is going to become available in the Philippines. Pamorelin, and Decapeptyl® will be made available to urologists and oncologists who treat men with advanced prostate cancer. It will be available in one, three and six month formulations. Pamorelin is an agonist analogue of the natural gonadotropin-releasing hormone (GnRH). It is designed to chemically castrate men so that their advanced prostate cancer will not have the male androgens needed to feed the prostate cancer.